trending Market Intelligence /marketintelligence/en/news-insights/trending/5eJCWTM5Xz0yqKI3jbQGww2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Nutra Pharma receives US FDA warning letter

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Nutra Pharma receives US FDA warning letter

The U.S. Food and Drug Administration issued a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products with claims to treat multiple conditions.

According to the regulator, Nutra Pharma was selling products that have not proven to be safe or effective and was breaking the law by selling such products.

In addition, the regulator noted that the unapproved products, which were labeled as homeopathic, claimed to treat addiction and chronic pain, including pain associated with cancer, diabetes, shingles, fibromyalgia and other serious conditions.

The March 19 warning letter was issued for Nutra Pharma's Nyloxin oral spray, Nyloxin topical gel, Nyloxin topical roll-on, Nyloxin topical roll-on ES, Nyloxin professional size pump topical gel and regular strength sample pack. FDA also said that the names of these products are similar to approved drugs, which may confuse the consumers.

The FDA categorizes claims to prevent, treat or cure health conditions for products that have not proven safety and efficacy for such uses as health fraud scams.

Nutra Pharma has 15 days to respond and if the company fails to correct violations, the FDA can take legal action without further notice, including, without limitation, seizure and injunction.